Tag Archives: DPP4

Diabetes Medicines In DPP-4 Inhibitor Class Might Not Increase Risk Of Inflammatory Bowel Disease (IBD) 

But New Medical Study Finds That Januvia, Onglyza, Other Drugs In Class Significantly Increase Risk Of Crohn's Disease (CD)   (Posted by Tom Lamb at DrugInjuryWatch.com)   Back in March 2018 we wrote this report, "Januvia, Onglyza, And Certain Other … Continue reading

Posted in Health Law | Tagged , , , , , , , , , , , | Leave a comment

Diabetes Drugs In DPP-4 Inhibitor Class Associated With Almost Two-Times Increased Risk of Cholangiocarcinoma

Medical Researchers Finding This Rare But Highly Fatal Cancer Call For More Investigation Into This Possible Drug Side Effect   (Posted by Tom Lamb at DrugInjuryWatch.com)   A recent medical study shows that the use of diabetes medicines in the … Continue reading

Posted in Injury & Accident Law | Tagged , , , , , , , , , , | Leave a comment

DPP-4 Diabetes Drug Side Effects Include Heart Attacks And Strokes As Well As Heart Failure

Onglyza, Nesina, Januvia, and Tradjenta Are Included In This Popular Class Of Type-2 Diabetes Medications   (Posted by Tom Lamb at DrugInjuryWatch.com)   In April 2016 the FDA took regulatory action by mandating label changes with new warnings about an … Continue reading

Posted in Products Liability | Tagged , , , , , , , , , , | Leave a comment